Prasugrel
Administration
- Type: Antiplatelet
- Dosage Forms: 5, 10 mg
- Routes of Administration: Oral
- Common Trade Names: Effient
Adult Dosing
10 mg PO QD
- Start: 60 mg PO x1
- For patients undergoing PCI, give with aspirin 75-325 mg PO QD
- Consider decrease to 5 mg PO QD if < 60 kg
Pediatric Dosing
N/A
Special Populations
- Pregnancy Rating: B; No known risk of fetal harm based on animal data at up to 30x MRHD
- Lactation risk: L3; Safety unknown
Renal Dosing
- Adult: No adjustment
- Pediatric: N/A
Hepatic Dosing
- Adult: No adjustment for mild impairment. Not defined for severe impairment.
- Pediatric: N/A
Contraindications
Adverse Reactions
Serious
- Severe bleeding
- Hemorrhage
- TTP
- Thrombocytopenia
- Anemia
- Leukopenia
- Hepatic impairment
- Atrial fibrillation
Common
- Bleeding
- Hypertension
- Hyperlipidemia
- Headache
- Back pain
- Dyspnea
- Nausea
- Dizziness
- Cough
- Hypotension
- Fatigue
- Chest pain
- Atrial fibrillation
- Bradycardia
- Leukopenia
- Rash
- Fever
- Peripheral edema
- Extremity pain
- Diarrhea
Pharmacology
- Half-life: 7 hr
- Metabolism: Liver; CYP450: 2B6, 2C9/19 (minor), 3A4 substrate
- Excretion: Urine 68%, feces 27%
Mechanism of Action
Irreversibly binds to P2Y12 adenosine diphosphate receptors, reducing platelet activation and aggregation.
Comments
See Also
References
This article is issued from
Wikem.
The text is licensed under Creative
Commons - Attribution - Sharealike.
Additional terms may apply for the media files.